Literature DB >> 12910569

Treatment with infliximab for a child with Behçet's disease.

Frank T Saulsbury1, James A Mann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12910569     DOI： 10.1002/art.11204

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  13 in total

1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 2.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

3.  Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinism.

Authors:  Lois M Endo; Steven M Rowe; Robb L Romp; Mark A Buckmaster; T Prescott Atkinson
Journal:  Clin Rheumatol       Date:  2006-09-19       Impact factor: 2.980

4.  Infliximab in a child with therapy-resistant systemic vasculitis.

Authors:  Sandra W K de Kort; Marion A J van Rossum; Rebecca ten Cate
Journal:  Clin Rheumatol       Date:  2005-11-03       Impact factor: 2.980

Review 5.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 6.  Clinical Manifestations and Management of Pediatric Behçet's Disease.

Authors:  Ya-Chiao Hu; Bor-Luen Chiang; Yao-Hsu Yang
Journal:  Clin Rev Allergy Immunol       Date:  2021-10       Impact factor: 8.667

Review 7.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 8.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Authors:  Massimo Accorinti; Maria Pia Pirraglia; Maria Pia Paroli; Roberta Priori; Fabrizio Conti; Paola Pivetti-Pezzi
Journal:  Jpn J Ophthalmol       Date:  2007-06-07       Impact factor: 2.447

Review 10.  A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.

Authors:  Shojiro Watanabe; Tomomi Aizawa-Yashiro; Kazushi Tsuruga; Manabu Kinjo; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2012-12-25       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.